Ningetinib
As of the edition of 20 October 2026, Ningetinib is a small molecule: stopped in 2024; acts on AXL, FLT3 and MERTK and 1 more.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2024
- Kind
- Small molecule
- Registered trials
- 7, 5 stopped early
- Disease areas
- Cancer; Lungs and airways; Blood and lymph
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
8 company-target rows on route A because of this drug.
Companies on route A for this drug
In the product8 company-target rows are on route A because of Ningetinib.
See the 8 company-target rows on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Targets
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 2 | 1 | 0 | 1 |
| Phase 2 | 5 | 1 | 0 | 4 |
| All trials | 7 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Sunshine Lake Pharma | Lead sponsor of trials | 2014 to now |
| Jiangsu Alphamab Biopharmaceuticals | Lead sponsor of trials | 2019 to now |